A major cause of increased blood glucose levels in type 2 diabetes (T2D) is increased hepatic gluconeogenesis (GNG), as the liver converts various substrates into glucose. Two of these substrates include glycerol, a molecule from fat, and lactate, a molecule that circulates in the blood. Our previously collected data suggest that glycerol's role in this process has been underestimated, so the investigators will directly compare the carbon contribution of glycerol and lactate to new glucose production under fasting conditions in patients with and without T2D. The investigators will also assess how glucagon, a hormone that raises blood glucose levels, impacts the conversion of glycerol and lactate to glucose. Enrolled participants will undergo three separate isotope tracer infusions with serial blood collections for liquid chromatography-mass spectrometry analysis. This research could identify new therapeutic drug targets that can lower blood glucose levels more directly and effectively.

Start Date01 Jul 2026

Sponsor / Collaborator

Rutgers State University of New Jersey

ACTRN12625000617460

/ Not yet recruitingPhase 2IIT

Hypertonic Glucose vs Insulin-dextrose to Prevent HypoGlycaemia following treatment for HyperKalaemia (HIGH K): A randomised controlled trial in adult participants

Start Date02 Feb 2026

Sponsor / Collaborator

The University of Queensland

NCT05985135

/ Not yet recruitingNot ApplicableIIT

Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus and Diabetes After Total Pancreatectomy

This research is being done to better understand how insulin effects muscle, blood, and the body in people with Type 1 Diabetes.

Start Date01 Dec 2025

Sponsor / Collaborator

Mayo Clinic

100 Clinical Results associated with Dextrose

100 Translational Medicine associated with Dextrose

100 Patents (Medical) associated with Dextrose

5,222

Literatures (Medical) associated with Dextrose

31 Dec 2025·Journal of the International Society of Sports Nutrition

Effect of different sports drink compositions on endurance performance and substrate oxidation: a randomized, double-blind, placebo-controlled crossover study in trained athletes

Article

Author: Moehle, Martin ; Ketelhut, Sascha ; Hottenrott, Laura

BACKGROUND:

The consumption of sports drinks before, during, and after endurance exercise is a common practice among athletes. These drinks typically contain a variety of components, each of which has been shown to offer individual benefits. However, the combined effects of these components, as formulated in many sports drinks, have not been thoroughly investigated. This study aims to evaluate the impact of typical sports drink components on endurance performance, perceived exertion, and carbohydrate and fat metabolism, using a sequential additive design.

METHODS:

Twelve healthy, trained endurance athletes aged 20 to 35 years participated in a randomized, double-blind, placebo-controlled study. The study involved a baseline assessment and four exercise protocols, each separated by a 7-day washout period. During each exercise protocol, participants cycled for 40 minutes at 80% of their previously determined peak oxygen uptake , followed by an incremental protocol performed to voluntary exhaustion. Participants were randomly assigned to ingest one of four 300 ml solutions 60 and 30 minutes before each exercise protocol: solution A (placebo mineral water), solution B (dextrose and sodium), solution C (solution B + beetroot extract), or solution D (solution C + arginine and L-citrulline). Ventilation and heart rate were continuously monitored before and throughout the exercise. Lactate and glucose levels were measured at specific time points before and during the exercise, while ratings of perceived exertion were recorded every 10 minutes. Power output was continuously tracked throughout the exercise protocol. Body weight was assessed both before and after each exercise session.

RESULTS:

There were no significant differences between the four solutions in terms of time to exhaustion (p = .703), power output (p = .822), peak oxygen uptake (p = 990), maximum lactate concentration (p = .720), and maximum heart rate (p = .884). During the exercise, no significant differences were observed in lactate and glucose concentrations, heart rate, or ventilatory parameters (ps > .050). However, significant differences (p < .001) in blood glucose concentrations were noted at rest and during the warm-up phase.

CONCLUSIONS:

The effect of the tested sports drink compositions on performance during the selected exercise protocol to voluntary exhaustion appears minimal. This study found no significant differences between the solutions and the placebo. Thus, it can be concluded that consuming a dextrose-based solution before exercise did not offer any performance advantage over water. The additional substances included in solutions B, C, and D did not influence performance, carbohydrate metabolism, or fat metabolism during the exercise.

01 Oct 2025·Clinical Nutrition ESPEN

Effects of glucose and fructose supplementation on serum sex hormone-binding globulin and testosterone levels: Post-hoc analysis of a double-blind randomized controlled trial

Article

Author: Brouwers, Martijn C G J ; Schalkwijk, Casper G ; Simons, Pomme I H G ; van der Ploeg, E M C ; Bons, J A P ; Simons, Nynke ; Feskens, Edith J M ; Chen, Huadong ; van de Waarenburg, Marjo P H

BACKGROUND&AIMS:

Previous laboratory studies have shown that simple sugars impair the hepatic synthesis of sex hormone-binding globulin (SHBG). This study aimed to assess whether fructose or glucose differentially affect serum SHBG and (free) testosterone levels in humans.

METHODS:

This is a secondary analysis of the FRUITLESS trial, a double-blind, randomized controlled study, including 36 participants (BMI ≥28 kg/m², fatty liver index ≥60). Participants followed a 6-week fructose-restricted diet and were supplemented with either fructose or glucose, matched to the amount of natural fructose that was removed from the diet. Differences between groups were analyzed using analysis of covariance (ANCOVA) with adjustment for sex.

RESULTS:

No significant differences were observed between fructose and glucose supplementation groups in serum SHBG (regression coefficient: +7.7 nmol/L, 95 % CI: -7.0; 22.4), total testosterone (+2.9 nmol/L, 95 % CI: -0.4; 6.2), or free testosterone (-1.9 pmol/L, 95 % CI: -93.0; 89.1). Sex-stratified analyses revealed similar results.

CONCLUSION:

Fructose and glucose supplementation do not differentially impact serum SHBG or (free) testosterone levels at a clinically meaningful level. The study was registered at ClinicalTrials.gov (NCT03067428) and were approved by the Medical Ethics Committee of Maastricht University Medical Center (NL58360.068.16).

01 Oct 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

A diet-based Drosophila melanogaster model for the in vivo pharmacological evaluation of α-glucosidase inhibitors

Article

Author: Lüersen, Kai ; Rimbach, Gerald ; Moody, Jones Olanrewaju ; Nebendahl, Melanie ; Oguntimehin, Samuel Ayoolu ; Olufolabo, Katherine Olabanjo ; Nevermann, Sandra

The intestinal α-glucosidases maltase and sucrase break down the dietary disaccharides maltose and sucrose respectively into their monosaccharides for absorption by the body. These enzymes are therefore drug targets for hyperglycaemia-associated metabolic diseases. Here, we tested whether the fruit fly Drosophila melanogaster is a suitable in vivo model for evaluating the efficacy, specificity and tolerability of α-glucosidase inhibitors. To this end, we fed flies with different obesity-inducing high-sugar diets based on glucose, fructose, maltose and sucrose, respectively. The different types of dietary sugar allow the distinction between processes that require maltase or sucrase activity and those that are not related to α-glucosidase activity. Accordingly, administration of the established general α-glucosidase inhibitor acarbose reduced the triacylglyceride levels only in disaccharide-based diets. This was associated with a delayed larval development, a shortened lifespan and reduced spontaneous locomotor activity. Similar effects were not observed with monosaccharide-based diets. We conclude that acarbose is effective, selective, and well tolerated by the fly. By applying the same method approach, the root bark of the African mulberry Morus mesozygia was proved to be a potent in vivo inhibitor of maltase without side effects on the development and lifespan of D. melanogaster. We suggest that this convenient diet-based in vivo model is valuable even via non-invasive methods for evaluating novel drugs and bioactives with α-glucosidase inhibitory activity.

News (Medical) associated with Dextrose

11 Jun 2025

·www.fiercebiotech.com

Tandem Diabetes Care to link insulin pump with Abbott\'s upcoming glucose-ketone wearable

Tandem said the agreement with Abbott includes plans to offer an integrated diabetes solution. \n Tandem Diabetes Care announced plans to link its automated insulin delivery systems with an upcoming wearable monitor from Abbott that aims to measure blood glucose as well as ketone levels.The dual sensor, which has been under development for years, is designed to help users spot the early signs of diabetic ketoacidosis, a life-threatening condition that can develop in some people with Type 1 diabetes. “Integrating our advanced insulin delivery systems with Abbott’s future glucose-ketone sensor has the potential to help empower people with diabetes to take faster, more informed action to protect their health and improve outcomes,” Tandem’s president and CEO, John Sheridan, said in a statement. Tandem also said the agreement includes plans to commercialize an integrated diabetes solution. Abbott has said that its new sensor will be built on its FreeStyle Libre 3 continuous glucose monitoring platform and will be the same size, and that it will also work with the company’s suite of digital tools. The system previously received a breakthrough designation from the FDA in 2022. And Tandem isn’t the only company waiting in line. Last month, the insulin delivery newcomer Sequel Med Tech said its twiist pump would also connect with Abbott’s planned device, once it receives regulatory clearance and is made available in the U.S.Sequel, a recently named Fierce Medtech Fierce 15 winner, is now in the process of rolling out its twiist automated insulin delivery system; the company previously announced that it would work with Abbott’s current FreeStyle Libre 3 Plus, as well as Senseonics’ 365-day Eversense CGM.

$Tandem Diabetes Care to link insulin pump with Abbott\'s upcoming glucose-ketone wearable$

Breakthrough Therapy

10 Jun 2025

·www.businesswire.com

Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. "Integrating our advanced insulin delivery systems with Abbott’s future glucose-ketone sensor has the potential to help empower people with diabetes to take faster, more informed action to protect their health and improve outcomes," said John Sheridan, president and chief executive officer. "We are excited to continue our partnership with Abbott and look forward to working with them to bring this new integration to customers in the future." About Tandem Diabetes Care, Inc. Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com. Follow @TandemDiabetes on Facebook, Instagram, LinkedIn, TikTok, and X. Forward-looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, development plans to integrate Tandem insulin delivery systems with Abbott dual glucose and ketone sensing technology. These forward-looking statements are subject to numerous risks and uncertainties, including risks, for example, that technical challenges, clinical or regulatory hurdles or other factors may prevent or delay integration, as well as other risks identified in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents that we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors. ©2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.

22 May 2025

·www.globenewswire.com

Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott’s Future Dual Glucose-Ketone Sensor

Integration of Abbott’s glucose-ketone sensor with the twiist™ AID System aims to enhance early identification of rising ketones to detect the risk of diabetic ketoacidosis (DKA)1MANCHESTER, N.H., May 22, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies today announced a commercial development agreement for future integration of Sequel’s twiist™ Automated Insulin Delivery (AID) System powered by Tidepool, with Abbott’s glucose-ketone sensor, currently under development. The agreement aims to improve outcomes for people with type 1 diabetes by adding ketone sensing capabilities to a Libre glucose sensor in combination with the twiist AID System to enable earlier detection of rising ketones. Regular measurement of ketones has been shown to reduce the risk of diabetic ketoacidosis in people living with type 1 diabetes2. Sequel’s expanded integration with Abbott’s sensor underscores the company’s commitment to delivering more choice, flexibility and confidence to people managing type 1 diabetes. “By integrating the twiist AID System with Abbott’s future glucose-ketone sensor, Sequel will be able to offer people with diabetes greater choice and the potential for improved outcomes in managing their care. twiist was designed to rapidly identify interruptions in insulin delivery, so combining this with early identification of rising ketones could help people living with diabetes react more quickly and more confidently,” said Sequel CEO and Co-Founder Alan Lotvin, M.D. “Through this collaboration, we are redefining what people living with diabetes can expect from an AID system.” People living with type 1 diabetes who use twiist will be able to select from compatible CGM systems, including Abbott’s FreeStyle Libre® 3 Plus sensor and, in the future, the Senseonics Eversense 365 to best suit their individual needs for managing diabetes. Abbott’s glucose-ketone sensor will be added in the future once the product is cleared for use and available in the U.S. The twiist AID System features proprietary iiSure™ Technology, which directly measures the volume of insulin delivered with each micro-dose. It includes four checkpoints that measure the insulin quantity delivered and enables the system to alert users to blockages up to nine times faster than competing AID systems3. Cleared for people ages six and up with type 1 diabetes, the twiist AID System offers the capability and flexibility to address each person’s individual dosing needs. The twiist Loop algorithm, based on Tidepool Loop, an intuitive and smart technology designed by people with diabetes for people with diabetes, allows the system to automatically adjust basal insulin delivery based on real-time sensor readings and predicted glucose levels. You can learn more about twiist, set to be commercially available in Q2 2025, and sign up for the latest updates on availability at www.twiist.com. About Sequel Med Tech Headquartered in Manchester, N.H., Sequel Med Tech, LLC is developing the next generation of transformative drug-delivery advancements. Sequel’s approach is to look at disease management holistically to advance systems that make living with disease simpler and easier for all. Its FDA-cleared innovation, the twiist® Automated Insulin Delivery (AID) system, integrates novel technologies to reimagine insulin delivery and sets a new standard for drug delivery. Co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare visionary Alan Lotvin, MD. Sequel is bringing the latest developments in science and technology to help drive more accessible drug delivery. For more information, visit sequelmedtech.com and twiist.com. Sequel Media ContactGreta GustafsonHighwire PRsequel.med.tech@highwirepr.com Cherubini, V., Grimsmann, J.M., Åkesson, K. et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia 63, 1530–1541 (2020).Misra S, Oliver NS. Utility of ketone measurement in the prevention, diagnosis and management of diabetic ketoacidosis. Diabet Med. 2015;32(1):14-23. doi:10.1111/dme.12604.Calculation based on a comparison of the following IFUs. The following reported 1 U/hr basal rate: Sequel Med Tech - twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide ; Insulet - Omnipod 5 Automated Insulin Delivery System User Guide ; Medtronic - MiniMed 780G system User Guide ; Beta Bionics - iLet Bionic Pancreas System User Guide. The following reported 2 U/hr basal rate: Tandem Diabetes Care - t:slim X2 Insulin Pump User Guide ; Tandem Diabetes Care - Tandem Mobi System User Guide.

License out/in

100 Deals associated with Dextrose

External Link

KEGG	Wiki	ATC	Drug Bank
D02325	Dextrose	-	DB09341

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Water-Electrolyte Imbalance	United States	Baxter Healthcare Corp.	25 Jan 1971

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 2	Slovakia	-	31 Mar 2023
Prediabetic State	Phase 2	Slovakia	-	31 Mar 2023
Obesity	Phase 2	Georgia	-	01 Nov 2022
Obesity	Phase 2	Germany	-	01 Nov 2022
Obesity	Phase 2	Puerto Rico	-	01 Nov 2022
Glycogen Storage Disease	IND Approval	China	Beijing CoSci Med-Tech Co., Ltd.	20 Jan 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03067428 (FRUITLESS, Pubmed \| Clin Nutr ESPEN)	Not Applicable	Obesity	36	Fructose supplementation	wnctmvfvyo(dqdnkrwtqy): Regression coefficient = 7.7 (95.0% CI, -7.0 to 22.4) View more	Positive	01 Oct 2025
				Glucose supplementation
NCT05803772 (GlobeNewswire) Manual	Phase 2	Prediabetic State	-	APHD-012	oobqkzgqxk(mwfekesaqv) = In a group of healthy, prediabetic and diabetic patients, APHD-012 (6 weeks treatment) reduced OGTT blood glucose levels at 120 minutes post-challenge from 9.00.6 to 7.90.6 mmol/L (n=23, p=0.01); placebo treatment in the same patients had no significant effect (8.80.4 mmol/L versus 8.50.6 mmol/L; p=0.33) zsffuptuwd (xkrlsjygtt ) View more	Positive	20 Jun 2024
				placebo
NCT01369147 (CTgov)	Phase 2	Critical Illness	12	Enteral feeding+Propofol+Clevidipine+Dextrose (Parenteral Nutrition Energy Dose at 0.6 x Measured REE)	mlqjgonhrd = sixzjzncoy qhleuxoxxb (rwxrjhvzed, gaqsmbgmqa - ihnodpxdqb) View more	-	10 Jun 2022
				Enteral feeding+Propofol+Clevidipine+Dextrose (Parenteral Nutrition Energy Dose at 1.0 x Measured REE)	mlqjgonhrd = zgeinxvfqv qhleuxoxxb (rwxrjhvzed, nxkniyhkdv - wbpurstgeg) View more
NCT05548738 (Pubmed \| J Altern Complement Med)	Phase 2/3	Leg/buttock pain	32	Caudal Epidural D5W	ayqmdnfvbf(bygdkowgma) = iwldjichdw tjqllektrh (dknefiqehp )	Positive	01 Dec 2018
NCT01866215 (Pubmed \| Am J Clin Nutr)	Not Applicable	-	8	Fructose	qkkikmbwmg(jbmsycbhay) = xhbotovyxr diviwicqsg (goyapgehlj ) View more	-	01 Mar 2017
				Glucose	qkkikmbwmg(jbmsycbhay) = alnwuqifkv diviwicqsg (goyapgehlj ) View more
NCT00475475 \| NCT01424306 (Pubmed \| Am J Clin Nutr)	Not Applicable	-	-	Aspartame-sweetened beverage	bdhlyvbebv(tzfmgvwiue) = mhxnlisrob lqsmeyaigl (abjamewhdj )	-	01 Dec 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis